Share AbbVie raised its annual profit outlook as Skyrizi and Rinvoq growth lifted third-quarter sales, strengthening the case that newer medicines can offset Humira’s decline.
$ABBV INSIGHTS →

abbv · signals · earnings · 4 min read · ♡ 29 · ▢ 0 · ↗ 0

AbbVie raised its annual profit outlook as Skyrizi and Rinvoq growth lifted third-quarter sales, strengthening the case that newer medicines can offset Humira’s decline.

· App research preview · Editorial standards

Read the full research in the app

A subscription is required to access the full thread.

Open in the app →
Financials
Technicals
Earnings-peers